Skip to main content
SpringerLink
Log in

D-CAG (decitabine followed by cytarabine, aclarubicin, and G-CSF) for relapsed acute myeloid leukemia after hematopoietic cell transplantation

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Wei G, Ni W, Chiao JW et al (2011) A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. J Hematol Oncol 4:46. doi:10.1186/1756-8722-4-46

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  2. Breccia M, Salaroli A, Serrao A et al (2013) Azacitidine as salvage therapy in elderly patients with relapsed acute myeloid leukemia after autologous transplantation. Ann Hematol 92(10):1413–1414. doi:10.1007/s00277-013-1732-2

    Article  PubMed  Google Scholar 

  3. Ganguly S, Amin M, Divine C et al (2013) Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT). Ann Hematol 92(4):549–550. doi:10.1007/s00277-012-1607-y

    Article  PubMed  Google Scholar 

  4. Issa JP, Garcia-Manero G, Giles FJ et al (2004) Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103(5):1635–1640. doi:10.1182/blood-2003-03-0687

    Article  PubMed  CAS  Google Scholar 

  5. Blum W, Klisovic RB, Hackanson B et al (2007) Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 25(25):3884–3891. doi:10.1200/JCO.2006.09.4169

    Article  PubMed  CAS  Google Scholar 

  6. Welch JS, Niu H, Uy GL et al (2014) A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML. Am J Hematol 89(8):E103–E108. doi:10.1002/ajh.23735

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Ustun C, Kalla A, Farrow S et al (2008) Decitabine as “bridge therapy” to a MUD transplant in relapsed AML postautologous stem cell transplantation. Am J Hematol 83(10):825–827. doi:10.1002/ajh.21267

    Article  PubMed  Google Scholar 

  8. Phillips CL, Davies SM, McMasters R et al (2013) Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults. Br J Haematol 161(3):406–410. doi:10.1111/bjh.12268

    Article  PubMed  CAS  Google Scholar 

  9. Song LX, Xu L, Li X et al (2012) Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia. Ann Hematol 91(12):1879–1886. doi:10.1007/s00277-012-1550-y

    Article  PubMed  CAS  Google Scholar 

  10. Scandura JM, Roboz GJ, Moh M et al (2011) Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. Blood 118(6):1472–1480. doi:10.1182/blood-2010-11-320093

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Authorship

All authors gave final approval to the manuscript.

Author information

Author notes

    Authors and Affiliations

    1. Department of Hematology, First Affiliated Hospital of Guangzhou Medical University, No. 1 Kangda Road, Guangzhou, China, 510230

      Runhui Zheng, Chunyan Wang, Baodan Yu & Huo Tan

    2. Department of Pharmacy and Pharmacology, University of Bath, Bath, UK

      Bailu Xie

    3. Department of Pharmacy, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

      Bailu Xie

    4. Guangzhou Institute of Respiratory Disease, Guangzhou, China

      Jun Xu

    Authors
    1. Runhui Zheng
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Bailu Xie
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Chunyan Wang
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Baodan Yu
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Jun Xu
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Huo Tan
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Huo Tan.

    Additional information

    Runhui Zheng and Bailu Xie contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Zheng, R., Xie, B., Wang, C. et al. D-CAG (decitabine followed by cytarabine, aclarubicin, and G-CSF) for relapsed acute myeloid leukemia after hematopoietic cell transplantation. Ann Hematol 95, 157–159 (2016). https://doi.org/10.1007/s00277-015-2505-x

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s00277-015-2505-x

    Keywords

    Search

    Navigation